Background & Aims: In nonalcoholic fatty liver disease (NAFLD), the distinction between
steatosis and steatohepatitis (NASH) and the assessment of the severity of the disease rely on …

Background Non-alcoholic steatohepatitis (NASH) is a common type of chronic liver disease
that can lead to cirrhosis. Obeticholic acid, a farnesoid X receptor agonist, has been shown …

The exclusion of other chronic liver diseases including “excess” alcohol intake has until now
been necessary to establish a diagnosis of metabolic dysfunction-associated fatty liver …

Hepatocellular carcinoma (HCC) can have viral or non-viral causes 1 , 2 , 3 , 4 – 5 . Non-alcoholic
steatohepatitis (NASH) is an important driver of HCC. Immunotherapy has been …

Short‐term trials of glitazones in nonalcoholic steatohepatitis (NASH) yielded controversial
histological results. Longer treatment might result in additional improvement. After a 1‐year …

Background Liver biopsy is thought mandatory for management of patients with hepatitis C
virus (HCV) infection, especially for staging fibrosis. We aimed, in our prospective study, to …

More than 400 million people worldwide are chronically infected by the hepatitis B virus. The
virus is responsible for more than 300000 cases of liver cancer every year and for similar …

Background Nonalcoholic steatohepatitis (NASH) is a common disease that is associated
with increased morbidity and mortality, but treatment options are limited. The efficacy and …

Nonalcoholic fatty liver disease is a common cause of chronic liver disease in the general
population. Nonalcoholic steatohepatitis (NASH), the aggressive form of nonalcoholic fatty …

Background Patients with non-alcoholic steatohepatitis (NASH)-related cirrhosis are at high
risk of liver-related and all-cause morbidity and mortality. We investigated the efficacy and …